Phase 3 trial

December 18, 2018

Phase 3 Trial to Test GPS Vaccine as Maintenance Therapy in High-risk Acute Myeloid Leukemia Patients

News

SELLAS Life Sciences announced plans for a newly streamlined Phase 3 trial to evaluate its investigational vaccine galinpepimut-S (GPS) as maintenance therapy for high-risk acute myeloid leukemia (AML) patients. If trial ... Read more

November 21, 2018November 21, 2018

Opdivo-Yervoy Combo Shows Durable Survival Benefits for Advanced Melanoma Patients in Phase 3 Trial

News

A combination of Bristol-Meyer Squibb‘s Opdivo (nivolumab) and Yervoy (ipilimumab) is more effective than either of the treatments alone as a first-line therapy for patients with advanced melanoma, according to ... Read more

November 2, 2018November 2, 2018

Keytruda-Inlyta Combo Extends Survival in Advanced Renal Cell Carcinoma Patients, Phase 3 Trial Shows

News

A combination of Keytruda (pembrolizumab) and Inlyta (axitinib) significantly extended the lives of patients with advanced renal cell carcinoma (RCC) and delayed disease progression or death, according to a Phase 3 clinical trial. ... Read more

March 12, 2018March 12, 2018

Phase 3 Trial of Idera’s IMO-2125 Combo Therapy Is Recruiting Advanced Melanoma Patients

News

A new Phase 3 trial for advanced melanoma patients who failed to respond to Opdivo (nivolumab) or Keytruda (pembrolizumab) is recruiting participants to evaluate Idera Pharmaceutical‘s experimental immunotherapy, IMO-2125, in combination with ... Read more

December 14, 2017

Genentech Combo Delays Kidney Cancer Progression, Phase 3 Trial Shows

News

A combination of the immunotherapies Tecentriq (atezolizumab) and Avastin (bevacizumab) increased the time it took kidney cancer to progress, compared with the standard treatment Sutent (sunitinib), a Phase 3 clinical trial shows. ... Read more

December 5, 2017December 5, 2017

Phase 3 Opdivo Trial Ends Early After Showing Better Survival Rates than Docetaxel in NSCLC

News

A Phase 3 study comparing Opdivo (nivolumab) to Taxotere (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC) who didn’t respond to platinum-based chemotherapy was ended early after an independent ... Read more

July 19, 2017

Opdivo Extends Survival, Has Less Impact on Lives in Head and Neck Cancer Patients Than Standard Chemo, Study Shows

News

The immunotherapy Opdivo (nivolumab) is less aggressive than standard-of-care chemotherapy for patients with recurrent or metastatic head and neck cancer, and has less of an impact on patients’ quality of ... Read more

June 26, 2017June 27, 2017

Cash-strapped ImmunoCellular Reviews ICT-107 Status, Suspends Phase 3 Trial for Glioblastoma

News

ImmunoCellular Therapeutics has suspended further patient randomization in its Phase 3 trial for its ICT-107, after determining that it cannot secure enough funding to complete the trial (NCT02546102). The study was to ... Read more